A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Pegozafermin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms ENLIVEN
- Sponsors 89bio
- 27 Feb 2025 According to a 89bio media release, data analyses from the Phase 2b ENLIVEN trial highlighting the potential anti-fibrotic effects and the potential utility of non-invasive tests correlating with histological endpoints were presented at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting in November 2024.
- 07 Feb 2025 Status changed from active, no longer recruiting to completed.
- 15 Nov 2024 According to a 89bio media release, company will present additional analyses from our Phase 2b ENLIVEN trial at this year's Liver Meeting.